ScreenerHero
PAHCPhibro Animal Health Corporation Class A
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · pahc.com
35.55USD+0.31%Mkt Cap: 1.44B $P/E: 15.21

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.44B $
Enterprise Value2.14B $
Revenue (TTM)1.50B $
Gross Profit399.94M $
Net Income (TTM)48.26M $
Revenue/Share37.00 USD
Last Price35.55 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS71742Q1067
Valuation
P/E (Trailing)15.21
P/E (Forward)10.52
PEG1.68
EV/EBITDA9.11
EV/Revenue1.43
P/S0.95
P/B3.94
EPS (TTM)2.31
EPS (Forward)3.34
52W Range
28.2523% of range60.08
52W High60.08 USD
52W Low28.25 USD
Profitability
Gross Margin30.85%
Oper. Margin12.56%
EBITDA Margin15.65%
Profit Margin3.72%
ROE16.89%
ROA3.55%
Growth
Revenue Growth10.30%
Earnings Growth15.70%
Cash Flow & Leverage
Operating CF80.12M $
CapEx (TTM)38.29M $
FCF Margin-1.18%
FCF Yield-1.23%
Net Debt710.54M $
Net Debt/EBITDA3.03
Balance Sheet
Debt/Equity2.67
Current Ratio3.17
Quick Ratio1.06
Book Value/Sh8.920 USD
Cash/Share1.926 USD
Dividends
Fwd Div Rate0.4800 USD
Trail. Div Rate0.4800 USD
Div. Yield1.35%
5Y Avg Yield2.55%
Payout Ratio20.60%
Ex-Div DateSep 2, 2026
Pay DateSep 23, 2026
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)45.00 USD
Upside (mean)+26.6%
Target Range35.00 USD – 58.00 USD
$35.00+26.6% to mean$58.00
# Analysts5
Ownership
Shares Out.21.07M
Float20.87M
Insiders0.87%
Institutions103.63%
Short Interest
Short Ratio4.5d
Short % Float6.73%
Short % Out.2.94%
Shares Short1.19M
Short (prev mo.)1.22M
Technical
SMA 5033.55 (+6.0%)
SMA 20042.23 (-15.8%)
Beta0.46
S&P 52W Chg18.16%
Avg Vol (30d)212.51K
Avg Vol (10d)150.87K
Technical Indicators
RSI (14)55.8
MACD0.1445
MACD Signal0.2693
MACD Hist.-0.1248
BB Upper37.50 USD
BB Middle35.16 USD
BB Lower32.83 USD
BB Width13.28%
ATR (14)1.340 USD
Vol Ratio (20d)0.90x